Vital Therapies reported $-21901000 in Net Income for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Biomarin Pharmaceutical BMRN:US $ 27.66M 93.13M
Dynavax Technologies DVAX:US $ 128.76M 95.9M
Enanta Pharmaceuticals ENTA:US $ -31.7M 1.89M
Epizyme EPZM:US $ -35.74M 19.76M
Insmed INSM:US $ -95645000 1.02M
Intercept Pharmaceuticals ICPT:US $ -7.53M 9.76M
Mirati Therapeutics MRTX:US $ -176.44M 11.94M
Revance Therapeutics RVNC:US $ -61.44M 2.91M
Ultragenyx Pharmaceutical RARE:US $ -158.16M 5.84M
United Therapeutics UTHR:US $ 116M 123.9M
Vital Therapies VTL:US $ -21.9M 1.09M
Xoma XOMA:US $ -4670000 2.39M